Nature's antivenom: Combinations of conserved rattlesnake serum metalloproteinase inhibitors block the lethal action of viper venoms
Carroll, S.; Ukken, F. P.; Ayinuola, Y. A.; Escalana, L.; Suntravat, M.; Sanchez, E. E.
Show abstract
Snakebite maims or kills several hundred thousand people each year. For more than a century, treatment has relied on antivenoms derived from animals immunized with whole venoms, but their efficacy, safety, and availability are highly variable, and it is often not well understood which specific venom components must be inhibited to prevent mortality and major morbidities. New therapeutic approaches are needed. Here, we take an evolutionary approach to antivenom design inspired by the longstanding observation that vipers have evolved serum-borne toxin inhibitors that confer resistance to their own venoms. We have investigated the abilities of a family of four rattlesnake metalloproteinase (MP) inhibitors derived from the ancestral serum glycoprotein Fetuin-A (FETUAs) to neutralize the enzymatic, hemorrhagic, and lethal activities of viper venoms. We find that while certain individual FETUA proteins are able to inhibit enzymatic or hemorrhagic activity, they are unable or only partially able to inhibit venom lethality. However, we show that specific combinations of FETUA proteins complement one anothers activities and are sufficient to fully neutralize rattlesnake venom lethality with approximately 10 times greater potency than commercial antivenom. Moreover, we demonstrate that FETUA proteins are well-conserved among viper subfamilies and that rattlesnake FETUAs are able to inhibit the MPs and neutralize the lethality of several evolutionarily distant pit viper or true viper venoms. Our results highlight the critical importance of inhibiting MPs in hemorrhagic venoms and the potential general utility of combinations of naturally evolved, recombinant MP inhibitors in the treatment of viper snakebite. Significance StatementSnakebite remains an undertreated tropical disease that affects over one million people annually, and new therapeutic approaches are needed. Here, we develop a novel approach to viper antivenoms inspired by the observations that these snakes are typically resistant to the hemorrhagic and lethal effects of their own venoms and that this resistance can be transferred to experimental animals through snake sera. We show that a small set of serum metalloproteinase inhibitors from the Western Diamondback rattlesnake are potent inhibitors of the lethality of its own venom, and able to block the lethality of other rattlesnakes and evolutionarily distant vipers. Recombinant natural antitoxins offer a promising approach for formulating more potent viper antivenoms.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Discerning Specific Thrombolytic Activities and Blood Clot Degradomes of Diverse Snake Venoms with Untargeted Peptidomics 96%
- Engineering a membrane-independent human prothrombinase through parsimonious mutation of factor Xa 92%
- Phage Display Broadly Identifies Inhibitor-reactive Regions in von Willebrand Factor 89%
Similar papers in this journal
Similar papers in this journal
- Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: results of preclinical efficacy testing 95%
- High throughput screening and identification of coagulopathic snake venom proteins and peptides using nanofractionation and proteomics approaches 95%
- Intraspecific venom variation in the medically important puff adder (Bitis arietans): comparative venom gland transcriptomics, in vitro venom activity and immunological recognition by antivenom 95%
Similar papers in this journal
- Toxin-like neuropeptides in the sea anemone Nematostella unravel recruitment from the nervous system to venom 92%
- A novel inhibitor of complement C5 provides structural insights into activation 92%
- A tripartite cytolytic toxin formed by Vibrio cholerae proteins with flagellum-facilitated secretion 91%
Similar papers in this journal
- Design of a Streptococcus pyogenes M protein immunogen to elicit M type cross-reactivity 93%
- Outer surface lipoproteins from the Lyme disease spirochete exploit the molecular switch mechanism of the complement protease C1s 92%
- Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.